Discovering and developing innovative therapeutics for CNS disorders

Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SIX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.

About Us

BoD

Professor Dr. Hanns Moehler - Director

  -
No Image

Professor Dr. Hanns Moehler held a professorship in the Department of Applied Biosciences, ETH Zurich, as well as in the Medical Faculty of the University of Zurich, where he was director of the Institute of Pharmacology, up to 2005. He was the first director of the Swiss National Center of Neuroscience Research (2000-2004), of which he is presently vice-director. Prior to his academic positions, Hanns Moehler gained extensive experience in industry as vice-director in the Research Department of Hoffmann-La Roche, Basle Switzerland. Prof. Möhler`s research was devoted to the neurobiology of brain disorders and their therapies. The research, which included the discovery of the benzodiazepine receptor and the drug Flumazenil, also encompassed the gene therapy of epilepsy, the neurobiology of emotions and the self-organisation of the brain. He is a member of the Swiss Academy of Medical Sciences and the European Academy of Sciences.

<< back